Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
Background: Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge.Novel treatment options for recurrent disease are an unmet need.Case: A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacit